COVID-19：SinovacとPfizer-BioNTech：香港の検証結果（動画）：
Chinese Vaccine Provides Inferior Immune Protection：
中国疫苗提供的免疫保护较差
ー中国製ワクチンは明らかに劣るー
中国製不活化ウイルスワクチン：
新規コロナウイルスに対し、最小限の保護のみ提供します。
香港の比較研究：
中国のワクチンに依存していた国々が、「なぜそんなに必死に苦しんでいるのか？」が、
今回判明しました。
SinovacワクチンとPfizer-BioNTechワクチンについて、
医療従事者のワクチン免疫原性の比較調査を実施。
医療従事者に対し、
ワクチン接種前に血液サンプルを収集しました。
2回目の投与前、
および2回目の投与後21〜35日。
They tested
for antibodies to SARS-CoV-2 using an ELISA to detect antibodies that bind to the receptor-binding domain of the spike protein.They also tested
specifically for neutralizing antibodies with a surrogate virus neutralization assay and then a plaque reduction neutralization test with live SARS-CoV-2.The study team
enrolled 1442 HCWs from public and private hospitals.In HCWs who received the BNT162b2 vaccine, antibody concentrations
measured by ELISA and sVNT rose substantially after the first dose and then rose again after the second dose of vaccination.
In a subset of 12 participants for whom we also had PRNT results, after the second dose,
the geometric mean PRNT50 titer was 269 and the geometric mean PRNT90 titer was 113.
In contrast,
the healthcare workers who received the inactivated vaccinehad low antibody concentrations by ELISA and sVNT after the first dose, rising to moderate concentrations after the second dose.
In a subset of 12 participants, after the second dose,
the geometric mean PRNT50 titer
was 27 and the geometric mean PRNT90 titer was 8·4.In summary,
the immune response (aka: immunogenicity) of the Sinovac vaccine is a fraction of what the Pfizer-BioNTech produces.
https://trialsitenews.com/chinese-vaccine-provides-inferior-immune-protection/